The Microscopy Facility, in existence at The Wistar Institute since 1973, provides a wide range of services for morphological analysis of biological structure at the light and electron microscopic level of resolution. The capabilities of the facility include the imaging of structure using light microscopy, fluorescence confocal microscopy, transmission electron microscopy assays, and scanning microscopy (performed at a remote location). The recent addition of the Leica confocal microscope in 1994 expanded the quality of service by providing state-of-the-art single cell assays and thick specimen analyses as well as high resolution in situ hybridization techniques. The facilities are located in the basement of the 1894 Building, occupying an area selected for the lowest magnetic fields and minimum vibration. Since the facility renovation in 1989, a total of 564 square feet is dedicated to the collective support of microscopy-related activities, including an office for the Director, Dr. Maul. During the current funding period, the facility housed two major pieces of equipment: A Leica confocal scanning microscope and a Leitz EM10 electron microscope equipped for stereo microscopy. The facility has contributed to the research of 30 Wistar investigators from Center-supported laboratories. The usage for current peer-reviewed projects was 29 percent, and for non-peer reviewed projects was 27 percent.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA010815-34S2
Application #
6595929
Study Section
Project Start
2002-03-01
Project End
2003-02-28
Budget Start
Budget End
Support Year
34
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414

Showing the most recent 10 out of 741 publications